Evan David Seigerman
Stock Analyst at BMO Capital
(3.25)
# 1,044
Out of 5,044 analysts
50
Total ratings
48.89%
Success rate
3.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan David Seigerman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk | Maintains: Market Perform | $50 → $55 | $52.05 | +5.67% | 7 | Oct 14, 2025 | |
| ABBV AbbVie | Maintains: Outperform | $215 → $240 | $227.54 | +5.48% | 8 | Sep 12, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $600 → $640 | $654.48 | -2.21% | 8 | Aug 4, 2025 | |
| REPL Replimune Group | Downgrades: Underperform | $27 → $2 | $10.45 | -80.86% | 4 | Jul 23, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $22 → $26 | $30.96 | -16.02% | 2 | Jun 12, 2025 | |
| MRUS Merus | Maintains: Outperform | $96 → $110 | $94.89 | +15.92% | 1 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $24 → $28 | $22.62 | +23.78% | 2 | May 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $20 → $10 | $9.50 | +5.26% | 1 | May 5, 2025 | |
| MRK Merck & Co. | Maintains: Market Perform | $105 → $96 | $87.03 | +10.31% | 4 | Feb 5, 2025 | |
| AMGN Amgen | Maintains: Outperform | $362 → $346 | $292.09 | +18.46% | 4 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $112 | $87.61 | +27.84% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $83 → $100 | $28.95 | +245.42% | 2 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 → $36 | $24.50 | +46.94% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $3 | $5.60 | -46.43% | 1 | May 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $369 → $396 | $820.10 | -51.71% | 1 | Sep 6, 2022 |
Novo Nordisk
Oct 14, 2025
Maintains: Market Perform
Price Target: $50 → $55
Current: $52.05
Upside: +5.67%
AbbVie
Sep 12, 2025
Maintains: Outperform
Price Target: $215 → $240
Current: $227.54
Upside: +5.48%
Regeneron Pharmaceuticals
Aug 4, 2025
Maintains: Outperform
Price Target: $600 → $640
Current: $654.48
Upside: -2.21%
Replimune Group
Jul 23, 2025
Downgrades: Underperform
Price Target: $27 → $2
Current: $10.45
Upside: -80.86%
Neurogene
Jun 12, 2025
Maintains: Outperform
Price Target: $22 → $26
Current: $30.96
Upside: -16.02%
Merus
May 23, 2025
Maintains: Outperform
Price Target: $96 → $110
Current: $94.89
Upside: +15.92%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $24 → $28
Current: $22.62
Upside: +23.78%
Arvinas
May 5, 2025
Maintains: Outperform
Price Target: $20 → $10
Current: $9.50
Upside: +5.26%
Merck & Co.
Feb 5, 2025
Maintains: Market Perform
Price Target: $105 → $96
Current: $87.03
Upside: +10.31%
Amgen
Jan 29, 2025
Maintains: Outperform
Price Target: $362 → $346
Current: $292.09
Upside: +18.46%
Nov 5, 2024
Maintains: Outperform
Price Target: $70 → $112
Current: $87.61
Upside: +27.84%
Jun 7, 2024
Maintains: Outperform
Price Target: $83 → $100
Current: $28.95
Upside: +245.42%
May 2, 2024
Reiterates: Outperform
Price Target: $33 → $36
Current: $24.50
Upside: +46.94%
May 15, 2023
Maintains: Outperform
Price Target: $9 → $3
Current: $5.60
Upside: -46.43%
Sep 6, 2022
Maintains: Outperform
Price Target: $369 → $396
Current: $820.10
Upside: -51.71%